144 related articles for article (PubMed ID: 9078354)
1. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery.
Sullivan KM; Storek J; Kopecky KJ; Jocom J; Longton G; Flowers M; Siadak M; Nims J; Witherspoon RP; Anasetti C; Appelbaum FR; Bowden RA; Buckner CD; Crawford SW; Deeg HJ; Hansen JA; McDonald GB; Sanders JE; Storb R
Biol Blood Marrow Transplant; 1996 Feb; 2(1):44-53. PubMed ID: 9078354
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease.
Sullivan KM
Clin Exp Immunol; 1996 May; 104 Suppl 1():43-8. PubMed ID: 8625543
[TBL] [Abstract][Full Text] [Related]
3. Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts.
Feinstein LC; Seidel K; Jocum J; Bowden RA; Anasetti C; Deeg HJ; Flowers ME; Kansu E; Martin PJ; Nash RA; Storek J; Etzioni R; Applebaum FR; Hansen JA; Storb R; Sullivan KM
Biol Blood Marrow Transplant; 1999; 5(6):369-78. PubMed ID: 10595814
[TBL] [Abstract][Full Text] [Related]
4. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?
Klaesson S; Ringdén O; Ljungman P; Aschan J; Hägglund H; Winiarski J
Transplantation; 1995 Dec; 60(11):1225-30. PubMed ID: 8525515
[TBL] [Abstract][Full Text] [Related]
5. Some but not all benefits of intravenous immunoglobulin therapy after marrow transplantation appear to correlate with IgG trough levels.
Cottler-Fox M; Lynch M; Pickle LW; Cahill R; Spitzer TR; Deeg HJ
Bone Marrow Transplant; 1991 Jul; 8(1):27-33. PubMed ID: 1655138
[TBL] [Abstract][Full Text] [Related]
6. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
Anderson D; DeFor T; Burns L; McGlave P; Miller J; Wagner J; Weisdorf D
Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
[TBL] [Abstract][Full Text] [Related]
7. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial.
Wagner JE; Thompson JS; Carter SL; Kernan NA;
Lancet; 2005 Aug 27-Sep 2; 366(9487):733-41. PubMed ID: 16125590
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation.
Sullivan KM; Kopecky KJ; Jocom J; Fisher L; Buckner CD; Meyers JD; Counts GW; Bowden RA; Peterson FB; Witherspoon RP
N Engl J Med; 1990 Sep; 323(11):705-12. PubMed ID: 2167452
[TBL] [Abstract][Full Text] [Related]
9. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group.
Wolff SN; Fay JW; Herzig RH; Greer JP; Dummer S; Brown RA; Collins RH; Stevens DA; Herzig GP
Ann Intern Med; 1993 Jun; 118(12):937-42. PubMed ID: 8489107
[TBL] [Abstract][Full Text] [Related]
10. Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation.
Siadak MF; Kopecky K; Sullivan KM
Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):53-7. PubMed ID: 8033436
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants.
Abdel-Mageed A; Graham-Pole J; Del Rosario ML; Longmate J; Ochoa S; Amylon M; Elfenbein GJ; Janiec J; Jansen J; Lazarus HM
Bone Marrow Transplant; 1999 May; 23(9):929-32. PubMed ID: 10338049
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
Winston DJ; Ho WG; Bartoni K; Champlin RE
Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
[TBL] [Abstract][Full Text] [Related]
14. Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation.
Sokos DR; Berger M; Lazarus HM
Biol Blood Marrow Transplant; 2002; 8(3):117-30. PubMed ID: 11939601
[TBL] [Abstract][Full Text] [Related]
15. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
Mengarelli A; Iori AP; Romano A; Cerretti R; Cerilli L; De Propris MS; Fenu S; Moleti ML; De Felice L; Girelli G; Arcese W
Haematologica; 2003 Mar; 88(3):315-23. PubMed ID: 12651271
[TBL] [Abstract][Full Text] [Related]
16. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
[TBL] [Abstract][Full Text] [Related]
17. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
18. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group.
List AF; Maziarz R; Stiff P; Jansen J; Liesveld J; Andrews F; Schuster M; Wolff S; Litzow M; Karanes C; Dahlberg S; Kirkhart B; Bianco JA; Singer JW
Bone Marrow Transplant; 2000 Feb; 25(3):283-91. PubMed ID: 10673700
[TBL] [Abstract][Full Text] [Related]
19. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
20. Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial.
Mevorach D; Zuckerman T; Reiner I; Shimoni A; Samuel S; Nagler A; Rowe JM; Or R
Biol Blood Marrow Transplant; 2014 Jan; 20(1):58-65. PubMed ID: 24140121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
